At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 192 enrolled
Drug / intervention
IC51 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study
In Brief
A Phase 3 clinical trial evaluating IC51, HAVRIX, and 1 other intervention for Japanese Encephalitis. Completed, enrolled 192 participants.
Detailed Summary
The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
Primary CompletionJul 2006
First PostedJan 2008
Study CompletionAug 2008
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartSep 1, 2005
Primary CompletionJul 1, 2006
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.5 years ago
Interventions
IC51biological
HAVRIXbiological
Placeboother